Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. Show more

101 Lindenwood Drive, Malvern, PA, 19355, United States

Biotechnology

Healthcare

Market Cap

73.8M

52 Wk Range

$1.54 - $5.50

Previous Close

$2.13

Open

$2.03

Volume

854,577

Day Range

$2.01 - $2.10

Enterprise Value

59.46M

Cash

19.53M

Avg Qtr Burn

-8.927M

Insider Ownership

13.88%

Institutional Own.

15.63%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Buntanetap (ANVS401) Details Alzheimer's disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Buntanetap (ANVS401) Details Parkinson's disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.